Loading...

Research

Join Now!

UK Cardio-Oncology Research Network

We want to promote multi-centre UK cardio-oncology research to change clinical outcomes for our patients, by ensuring that the research is well designed and collaborative, whilst maximising recruitment by linking researchers with clinicians and patients.

Ninian Lang - 2025
Hosted on this BC-OS.org website
- researchers ‘advertise’ interests, expertise and access to patient groups
- central point for identification of potential collaborators
- please contact us via research@BC-OS.org

Broad representation
- clinical trials, data and basic science - we are actively seeking more oncology/haematology research links - the KEY TO SUCCESS!
Aims
- multi-centre studies and successful funding applications
- expansion of cardio-oncology registries
- incorporation of translational science in clinical studies where appropriate
- optimise use of electronic data linkage
Cardio-Oncology Research Centres
Contact research@BC-OS.org or use the details below to get involved in cardio-oncology research

Aberdeen
Prof Dana Dawson and team, University of Aberdeen
Magnetic Resonance Spectroscopy Assessment of Cardiac and Skeletal Muscle Following Anthracycline Based Treatment for Breast Cancer. BCOS is part of the BHF CRC which provides infrastructure to support clinical research in UK, via coordination of activity and prioritisation of research identified as important by patients and other stakeholders.
Edinburgh
Dr Peter Henriksen and team, NHS Lothian/University of Edinburgh
Cardiac CARE: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity
Glasgow
Prof Ninian Lang and team, University of Glasgow
Prospective Characterisation of CV Effects of VEGF Inhibitors (EndoTOX)
Prospective Characterisation of CV Effects of BRAF/MEK Inhibitors in Melanoma (BioCOBRA)
FDG-PET Assessment of Immunotherapy/VEGFi Inflammatory Atheroma (BioCAPRI)
Cardiotoxicity of Carfilzomib: Stress Perfusion Magnetic Resonance Assessment
Clonal Haematopoiesis as a Risk Factor for Cardiotoxicity of Cancer Therapy
Belfast
Prof Mark Harbinson and team, Queen’s University, Belfast
Cancer and heart disease demographics. Linkage of NI cancer registry with NI hospital diagnostic codes
Middlesbrough
Dr David Austin and team, South Tees Academic Cardiovascular Unit/South Tees NHS Foundation Trust
Preventing cardiotoxicity in patients with breast cancer and lymphoma: a multicentre randomised controlled trial (PROACT)
Liverpool
Dr Rebecca Dobson, Dr David Gent and team, Liverpool Heart and Chest Hospital
Patient-derived pluripotent stem cells to understand mechanisms and preventive strategies for anthracycline cardiotoxicity. Characterisation of short and long-term adverse cardiovascular effects of stem cell transplants to improve risk-stratification.
Manchester
Prof Chris Miller and Prof John Radford, University of Manchester/NIHR Manchester Biomedical Research Centre (BRC)
Living with and Beyond Cancer: Improving Cardiovascular Health (cardio-onc registry, n=2,500 long-term data linkage)
Leicester
Dr David Adlam, University of Leicester
VICORI: Virtual Cardio-Oncology Research Initiative. Data linkage between National Cancer Registration and Analysis Service (NCRAS) and the six National Cardiovascular disease audits held by the National Institute for Cardiovascular Outcome Research (NICOR)
London
Prof Charlotte Manisty, Mark Westwood, Malcolm Walker, Arjun Ghosh, Tom Crake and team, Barts/UCL
HER2-targeted cardiotoxicity: RCT of withdrawal of HF meds in recovered LV. Optimising screening
Fluoropyrimidines: Prospective risk prediction study, mechanistic study
Linked data analysis (VICORI)
CAR-T cardiotoxicity: Longitudinal Characterisation
Cancer-CV associations in UK Biobank
Pharmacoepidemiology of CV drugs in patients with cancer
AI-based screening for cardiotox (prospective assessment)

Dr Alex Lyon and team, Royal Brompton and Harefield NHS Trust
CV toxicities of immunotherapy
AI in cardio-oncology
ESC Guidelines

Prof Theresa McDonagh, Dr Clare Bannister and team, Kings, London
Biomarkers and risk prediction for anthracycline cardiotoxicity
Recent Cardio-Oncology Research Publications

Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial
JACC: CardioOncology (2024) 6:684-696
Trial assessing the role of angiotensin-converting enzyme inhibitors in protectiong against anthracycline-associated cardiac dysfunction by Dr David Austin.
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial
Circulation (2023) 148:1680-1690
Trial assessing the role of beta blocker and angiotensin-converting enzyme inhibitors in protectiong against anthracycline-associated cardiac dysfunction by Prof Peter Henriksen and Prof Ninian Lang.
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Trial
JAMA (2023) 330:528-636
Trial assessing the role of prior statin therapy in preventing anthracycline-associated cardiac dysfunction.
Other Research Content

ICOS podcasts
Arjun, Ashutosh and Amyloidosis, Dr. Baliga's "Got Knowledge Doc", Dr. Susan Dent ASCO daily news...
ICOS podcast library
European Society of Cardiology cardio-oncology webinars
ESC webinars - click the link to see the webinar index - then choose cardio-oncology to filter
ESC webinar index
ESC Cardio-Oncology Audio Interviews
04/01/2021 - Long-term survivorship programmes - reality or fiction?
14/12/2020 - How can cardiologists and hematologists collaborate to improve cardio-oncology structures?
09/11/2020 - Cancer and Vascular Toxicity
13/03/2020 - Immunotherapy: the new tsunami
06/01/2020 - Cardiac Imaging in Cancer patients
02/12/2019 - Cancer and Heart failure: from prevention to treatment
21/10/2019 - When and why do we need a cardio-oncology service?
The index of interviews is here.

Contact BC-OS

E-mail
research@BC-OS.org